Athira Pharma, Inc. (ATHA)
| Market Cap | 96.59M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -116.19M |
| Shares Out | 38.33M |
| EPS (ttm) | -3.05 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 62,480 |
| Open | 2.510 |
| Previous Close | 2.510 |
| Day's Range | 2.460 - 2.590 |
| 52-Week Range | 1.330 - 4.298 |
| Beta | 2.92 |
| Analysts | Buy |
| Price Target | 19.00 (+653.97%) |
| Earnings Date | Aug 8, 2024 |
About ATHA
Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. Its lead product candidate is Fosgonimeton (ATH-1017), a small molecule designed to modulate the neurotrophic hepatocyte growth factor (HGF) system and its receptor, MET, for a healthy nervous system that is in LIFT-AD Phase 2/3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer's disease, as well as is in Phase 2 clinical trials to treat Parkinson's disease dementia and... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to one analyst, the rating for ATHA stock is "Buy" and the 12-month stock price forecast is $19.0.
News
Athira to Host Webinar Highlighting Potential for Fosgonimeton to Protect and Preserve Neuronal Health in Mild-to-Moderate Alzheimer's Disease Patients
Athira to Host Webinar Highlighting Potential for Fosgonimeton to Protect and Preserve Neuronal Health in Mild-to-Moderate Alzheimer's Disease Patients
Glancy Prongay & Murray LLP and Labaton Keller Sucharow LLP Announce Proposed Class Action Settlement on Behalf of Purchasers of the Publicly Traded Common Stock of Athira Pharma, Inc. - (NASDAQ: ATHA)
SEATTLE , June 10, 2024 /PRNewswire/ -- Nacif, et al. v. Athira Pharma, Inc., et al.
Athira Pharma to Participate in Upcoming June Conferences
Management to Highlight Robust Pipeline in Neurodegenerative Diseases with Key Phase 2/3 LIFT-AD Topline Data in Alzheimer's Disease on Track for Second Half of 2024 Management to Highlight Robust Pip...
Athira Pharma Announces Proposed Settlement of Stockholder Derivative Action
BOTHELL, Wash., May 17, 2024 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health an...
Athira Pharma Reports First Quarter 2024 Financial Results and Pipeline and Business Updates
Topline data from Phase 2/3 LIFT-AD clinical trial of fosgonimeton as a potential treatment for mild-to-moderate Alzheimer's disease expected in second half of 2024 Submitted Investigational New Drug...
Athira Pharma to Participate in Upcoming May Conferences
BOTHELL, Wash., May 02, 2024 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health a...
Athira Pharma Appoints Javier San Martin, M.D., as Chief Medical Officer
BOTHELL, Wash., April 15, 2024 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health ...
Athira Pharma Announces Publication of Preclinical Data Highlighting Fosgonimeton Treatment in Models of Alzheimer's Disease
BOTHELL, Wash., April 11, 2024 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health ...
Athira Pharma Announces Upcoming Poster Presentation at American Academy of Neurology (AAN) 2024 Annual Meeting
Presentation to highlight therapeutic potential of Athira's small molecules targeting the neurotrophic HGF system in neurodegenerative disorders, including Alzheimer's disease, Parkinson's disease and...
Athira Pharma Presents Clinical and Preclinical Data Supporting Therapeutic Potential of Fosgonimeton in Alzheimer's and Parkinson's Diseases at AD/PD™ 2024 International Conference
Athira Pharma Presents Clinical and Preclinical Data Supporting Therapeutic Potential of Fosgonimeton in Alzheimer's & Parkinson's Diseases at AD/PD™ 2024
Athira Pharma Reports Full Year 2023 Financial Results and Pipeline and Business Updates
Enrollment completed in Phase 2/3 LIFT-AD clinical trial of fosgonimeton as a potential treatment for mild-to-moderate Alzheimer's disease; topline data expected in second half of 2024 On track to in...
Athira Pharma Announces Publication in Frontiers in Neuroscience Highlighting Therapeutic Potential of ATH-1105 in Amyotrophic Lateral Sclerosis (ALS)
Athira Pharma Announces Publication in Frontiers in Neuroscience Highlighting Therapeutic Potential of ATH-1105 in Amyotrophic Lateral Sclerosis (ALS)
Athira Pharma Provides 2024 Clinical Pipeline Outlook and Business Update
Completed enrollment in Phase 2/3 LIFT-AD clinical trial of fosgonimeton as a potential treatment for mild-to-moderate Alzheimer's disease and expects topline data in second half of 2024 Plans to ini...
Athira Pharma Completes Enrollment of Phase 2/3 LIFT-AD Clinical Trial of Fosgonimeton in Mild-to-Moderate Alzheimer's Disease
Topline data from LIFT-AD on track for second half of 2024 Previously reported independent, unblinded interim analysis supports trial continuation and potential clinically meaningful activity of fosgo...
Athira Pharma Announces Encouraging Results from SHAPE Phase 2 Clinical Trial of Fosgonimeton for the Treatment of Parkinson's Disease Dementia and Dementia with Lewy Bodies
Exploratory findings add to increasing body of clinical and preclinical data supporting positive modulation of the neurotrophic HGF system as a potential therapeutic approach for neurodegenerative dis...
Athira Pharma to Participate in Sidoti December Small Cap Investor Conference
Company Presentation to highlight novel therapeutic candidates targeting the HGF neurotrophic system in late-stage clinical development in neurodegenerative diseases, including Alzheimer's disease Com...
Athira Pharma Presents Preclinical Data Highlighting Fosgonimeton's Neuroprotective Effects Against Amyloid-β-Induced Pathological Alterations and Neuroinflammation in Models of Alzheimer's Disease
BOTHELL, Wash., Nov. 15, 2023 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health a...
Athira Pharma to Participate in Jefferies London Healthcare Conference
BOTHELL, Wash., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health ...
Athira Pharma Presents Preclinical Data Further Supporting the Therapeutic Potential of ATH-1105 in Amyotrophic Lateral Sclerosis (ALS)
New results support the neuroprotective effects of ATH-1105 in preclinical models of ALS, as indicated by consistent reduction in plasma neurofilament light chain (NfL) levels and preservation of moto...
Athira Pharma to Participate in the 2023 Cantor Fitzgerald Global Healthcare Conference
BOTHELL, Wash., Sept. 19, 2023 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health...
Athira Pharma Reports Second Quarter 2023 Financial Results and Pipeline and Business Updates
Completed end of Phase 2 meeting and continu e d engagement with U.S. Food and Drug Administration Appointed Andrew Gengos as Chief Financial Officer and Chief Business Officer Maintains strong balanc...
Athira Pharma Presents Phase 2 Clinical Data Correlating Improvements in Biomarkers of Neurodegeneration and Neuroinflammation with Improvements in Measures of Cognition and Function in Alzheimer's Disease
New preclinical data demonstrate neuroprotective effects of fosgonimeton in models of amyloid-ß -mediated toxicity
Athira Pharma Announces Upcoming Presentations at the Alzheimer's Association International Conference (AAIC) 2023
Three poster presentations to highlight clinical and preclinical data across Athira's pipeline of neuroprotective therapeutic candidates Three poster presentations to highlight clinical and preclinica...
Athira Pharma Appoints Andrew Gengos as Chief Financial Officer and Chief Business Officer
Veteran biopharmaceutical executive brings over 30 years of financial, corporate strategy, transactional and business development experience Veteran biopharmaceutical executive brings over 30 years of...
Athira Pharma to Participate in Upcoming May Investor Conferences
BOTHELL, Wash., May 08, 2023 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health an...